MindMed Presents Alarming Data on Suicidal Ideation Among Adults with Generalized Anxiety Disorder at Psych Congress 2025 Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company pioneering the development of novel product candidates for brain health…
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 2025 Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress,…
In New DTC Ad Crackdown, FDA Trying to Close a Loophole That Isn’t While the FDA is trumpeting this new initiative as “sweeping reforms” to the way drug companies can advertise, experts say the regulator is going after a problem…
Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of convertible senior notes due…
Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75% convertible senior…
Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cat Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending…
WuXi Biologics Achieves “CDMO of the Year” Among Three Prestigious IMAPAC Awards WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it has received the “CDMO of the Year – Asia Pacific”, “Best Biologics…
QIAGEN Secures CE-IVDR Certification for Full QIAstat-Dx Portfolio, Expands Diagnostic Leadership with Enhanced Meningitis/Encephalitis Panel QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has announced a significant regulatory milestone: the company has secured CE-IVDR certification for its entire QIAstat-Dx syndromic…
Avanzanite Bioscience Strengthens Leadership with Appointment of Dr. Mark Bechter as Senior Vice President of Medical Affairs Avanzanite Bioscience B.V., a rapidly expanding European specialty pharmaceutical company dedicated to improving the lives of patients with rare diseases, announced today the…
Nuvig Therapeutics Strengthens Leadership Team with Appointment of David J. Woodhouse, Ph.D., as Chief Executive Officer and James Mackay, Ph.D., as Independent Board Chair Nuvig Therapeutics, Inc. (“Nuvig”), a privately held biotechnology company dedicated to developing transformative immunomodulatory therapeutics for…
Evonik and Ethris Forge Strategic Alliance to Redefine Nucleic Acid Delivery with Novel Lipid Nanoparticle Platform In a move that underscores the rapid evolution of nucleic acid-based medicines and the growing importance of advanced drug delivery technologies, Evonik, a global…
Alnylam Pharmaceuticals Launches $500 Million Convertible Senior Notes Offering to Strengthen Strategic Flexibility and Advance RNAi Pipeline Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the biotechnology pioneer recognized worldwide as the leader in RNA interference (RNAi) therapeutics, has announced the commencement of…